Clinical Trials in Iceland

• Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Not authorised
  2023-503969-36-00 Phase II Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Arctic Therapeutics ehf.
• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent… Pending
  2024-516723-14-00 Phase IV Rheumatoid Arthritis Karolinska Institutet
• Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple my… Pending
  2024-519353-11-00 Phase II Multiple Myeloma Landspitali
• A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia Pending
  2025-524044-35-00 Phase IV Dyspepsia Landspitali
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 Phase III Atherosclerotic cardiovascular disease (ASCVD) Novartis Pharma AG
• The Intensive Care Platform Trial (INCEPT) Recruiting
  2024-516208-41-00 Phase IV Acute critical illness requiring intensive care unit admissi… Rigshospitalet
• Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting
  2022-502221-18-00 Phase IV Recurrent non-muscle invasive bladder cancer Aarhus University
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit… Recruiting
  2023-505000-27-01 Phase II newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-ty… Prinses Maxima Centrum voor Kinderoncologie B.V.
• Non-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mil… Recruiting
  2024-513214-34-00 Phase II Distal Subungual Onychomycosis Moberg Pharma AB (publ)
• Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects with Alzheimer’s Disease (AD) Recruiting
  2024-519497-39-00 Phase II Alzheimer's Disease Arctic Therapeutics ehf.
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting
  2023-508196-36-00 Phase II Follicular lymphoma Karolinska University Hospital
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 Phase III Acute Myeloid Leukemia Prinses Maxima Centrum voor Kinderoncologie B.V.
• SACK Recruiting
  2022-501600-10-00 Phase III Atrial fibrillation and Chronic Kidney Disease stage 5 Karolinska University Hospital; Medical University Of Silesia Katowice Poland
• Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo… Recruiting
  2023-508963-58-00 Phase II Symptomatic hypertrophic cardiomyopathy (HCM) Cytokinetics Inc.
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 Phase II/III Acute Lymphoblastic Leukaemia Karolinska University Hospital
• Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Ended
  2023-503969-36-01 Phase II Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Arctic Therapeutics hf.
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended
  2022-501608-85-00 Phase III Cardiovascular disease (atherosclerotic cardiovascular disea… Amgen Inc.
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten… Ended
  2023-505514-15-00 Phase III Small-cell lung cancer, extensive stage Norwegian University Of Science And Technolology
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III Atherosclerotic cardiovascular disease (ASCVD) Novartis Pharma AG
• Vaginal progesterone as luteal support for improvement of live birth in frozen/thawed in-vitro fertilization natural cycles; a multicenter, … Ended
  2024-512844-40-00 Phase IV Infertility Vaestra Goetalandsregionen
• NORTH-REG Dwell-Time Study Ended
  2023-505936-37-00 Phase IV Urothelial cancer Aarhus University Hospital
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended
  2023-508292-37-00 Phase III Cardiovascular Disease Novartis Pharma AG
• Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati… Ended
  2023-508551-40-00 Phase IV Coronary artery multi-vessel disease and left main stenosis Vaestra Goetalandsregionen
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended
  2024-511096-15-00 Phase III Breast Cancer AstraZeneca AB

Showing 1–24 of 29 trials